Given that the modification of stem cell-derived extracellular vesicles (EVs) can enhance their regenerative efficiency, an increasing number of studies pay attention to the therapeutic potential of hypoxic preconditioning of stem cell-derived EVs (Hypo-EVs) in cardiac repair. Our meta-analysis aims to evaluate the cardiac repair of Hypo-EVs in preclinical animal models of myocardial infarction (MI). We searched PubMed, EMBASE, and the Web of Science up to January 2021. The primary outcome was left ventricular ejection fraction (LVEF). The second outcomes were left ventricular fractional shortening (LVFS) and infarct size. Random-effects modeling was used to calculate pooled weighted mean differences (WMDs) and 95% confidence intervals (CIs). Nine studies satisfied the inclusion criteria. Compared with the model group, pooled analyses demonstrated that stem cell-derived EVs culturing in normal oxygen environment (Nor-EVs) can improve LVEF (WMD: 9.07, 95% CI: 6.76 to 11.38, I2 = 80.7%), LVFS (WMD: 3.03, 95% CI: 0.79 to 5.27, I2 = 86.3%), and reduce infarct size (WMD: −12.15, 95% CI: −19.12 to −5.18, I2 = 96.8%). Compared with Nor-EVs, Hypo-EVs can improve LVEF (WMD: 5.11, 95% CI: 1.63 to 8.60, I2 = 95%), LVFS (WMD: 6.54, 95% CI: 4.08 to 8.99, I2 = 90.6%), and reduce infarct size (WMD: −7.42, 95% CI: −12.97 to −1.87, I2 = 97.2%). These results suggest that Hypo-EVs could show more improvement than Nor-EVs therapy on cardiac repair in the preclinical MI animal model. However, future well-designed large animal studies might be necessary to clarify the methods and effects of Hypo-EVs therapy to help provide new ideas for future engineered EVs design.
Get full access to this article
View all access options for this article.
References
1.
RothGA, JohnsonC, AbajobirA, Abd-AllahF, AberaSF, AbyuG, AhmedM, AksutB, AlamT, et al. (2017). Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol, 70:1–25.
2.
SenyoSE, SteinhauserML, PizzimentiCL, YangVK, CaiL, WangM, WuTD, Guerquin-KernJL, LecheneCP and LeeRT. (2013). Mammalian heart renewal by pre-existing cardiomyocytes. Nature, 493:433–436.
3.
PassierR, van LaakeLW and MummeryCL. (2008). Stem-cell-based therapy and lessons from the heart. Nature, 453:322–329.
4.
WysoczynskiM, KhanA and BolliR. (2018). New paradigms in cell therapy: repeated dosing, intravenous delivery, immunomodulatory actions, and new cell types. Circ Res, 123:138–158.
5.
van NielG, D'AngeloG and RaposoG. (2018). Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol, 19:213–228.
6.
GyorgyB, SzaboTG, PasztoiM, PalZ, MisjakP, AradiB, LaszloV, PallingerE, PapE, et al. (2011). Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci, 68:2667–2688.
7.
WiklanderOPB, BrennanMA, LotvallJ, BreakefieldXO and El AndaloussiS. (2019). Advances in therapeutic applications of extracellular vesicles. Sci Transl Med, 11:eaav8521.
8.
AdamiakM, ChengG, Bobis-WozowiczS, ZhaoL, Kedracka-KrokS, SamantaA, KarnasE, XuanYT, Skupien-RabianB, et al. (2018). Induced pluripotent stem cell (iPSC)-derived extracellular vesicles are safer and more effective for cardiac repair than iPSCs. Circ Res, 122:296–309.
9.
SahooS, KlychkoE, ThorneT, MisenerS, SchultzKM, MillayM, ItoA, LiuT, KamideC, et al. (2011). Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity. Circ Res, 109:724–728.
BarileL, CervioE, LionettiV, MilanoG, CiulloA, BiemmiV, BolisS, AltomareC, MatteucciM, et al. (2018). Cardioprotection by cardiac progenitor cell-secreted exosomes: role of pregnancy-associated plasma protein-A. Cardiovasc Res, 114:992–1005.
13.
BarileL, LionettiV, CervioE, MatteucciM, GherghiceanuM, PopescuLM, TorreT, SiclariF, MoccettiT and VassalliG. (2014). Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res, 103:530–541.
14.
GalletR, DawkinsJ, ValleJ, SimsoloE, de CoutoG, MiddletonR, TseliouE, LuthringerD, KrekeM, et al. (2017). Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J, 38:201–211.
15.
TengX, ChenL, ChenW, YangJ, YangZ and ShenZ. (2015). Mesenchymal stem cell-derived exosomes improve the microenvironment of infarcted myocardium contributing to angiogenesis and anti-inflammation. Cell Physiol Biochem, 37:2415–2424.
16.
YangL, ZhuJ, ZhangC, WangJ, YueF, JiaX and LiuH. (2019). Stem cell-derived extracellular vesicles for myocardial infarction: a meta-analysis of controlled animal studies. Aging (Albany NY), 11:1129–1150.
17.
de AbreuRC, FernandesH, da Costa MartinsPA, SahooS, EmanueliC and FerreiraL. (2020). Native and bioengineered extracellular vesicles for cardiovascular therapeutics. Nat Rev Cardiol, 17:685–697.
18.
BianS, ZhangL, DuanL, WangX, MinY and YuH. (2014). Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. J Mol Med (Berl), 92:387–397.
19.
Ribeiro-RodriguesTM, LaundosTL, Pereira-CarvalhoR, Batista-AlmeidaD, PereiraR, Coelho-SantosV, SilvaAP, FernandesR, ZuzarteM, et al. (2017). Exosomes secreted by cardiomyocytes subjected to ischaemia promote cardiac angiogenesis. Cardiovasc Res, 113:1338–1350.
20.
ZhuL-P, TianT, WangJ-Y, HeJ-N, ChenT, PanM, XuL, H-x Zhang, QiuX-T, et al. (2018). Hypoxia-elicited mesenchymal stem cell-derived exosomes facilitates cardiac repair through miR-125b-mediated prevention of cell death in myocardial infarction. Theranostics, 8:6163–6177.
21.
EguchiS, TakefujiM, SakaguchiT, IshihamaS, MoriY, TsudaT, TakikawaT, YoshidaT, OhashiK, et al. (2019). Cardiomyocytes capture stem cell-derived, anti-apoptotic microRNA-214 via clathrin-mediated endocytosis in acute myocardial infarction. J Biol Chem, 294:11665–11674.
22.
GrayWD, FrenchKM, Ghosh-ChoudharyS, MaxwellJT, BrownME, PlattMO, SearlesCD and DavisME. (2015). Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ Res, 116:255–263.
23.
AgarwalU, GeorgeA, BhutaniS, Ghosh-ChoudharyS, MaxwellJT, BrownME, MehtaY, PlattMO, LiangY, SahooS and DavisME. (2017). Experimental, systems, and computational approaches to understanding the microRNA-mediated reparative potential of cardiac progenitor cell-derived exosomes from pediatric patients. Circ Res, 120:701–712.
24.
DaiX, ZhaoL and LiuD. (2018). Exosomes from adipose-derived stem cells induce angiogenesis. J Extracell Vesicles, 7:166.
25.
DoughertyJA, PatelN, KumarN, RaoSG, AngelosMG, SinghH, CaiC and KhanM. (2020). Human cardiac progenitor cells enhance exosome release and promote angiogenesis under physoxia. Front Cell Dev Biol, 8:130.
26.
NamaziH, MohitE, NamaziI, RajabiS, SamadianA, Hajizadeh-SaffarE, AghdamiN and BaharvandH. (2018). Exosomes secreted by hypoxic cardiosphere-derived cells enhance tube formation and increase pro-angiogenic miRNA. J Cell Biochem, 119:4150–4160.
27.
KhanK, YuB, SchwertaniA and McCecereR. (2019). First characterization of extracellular vesicles derived from human amniotic stromal stem cells and their applications for cardiac repair and rejuvenation. Arteriosc Thromb Vasc Biol, 39:A201.
28.
MoherD, LiberatiA, TetzlaffJ, AltmanDG and GroupP. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6:e1000097.
29.
HozoSP, DjulbegovicB and HozoI. (2005). Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol, 5:13.
30.
HooijmansCR, RoversMM, de VriesRB, LeenaarsM, Ritskes-HoitingaM and LangendamMW. (2014). SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol, 14:43.
31.
EggerM, JuniP, BartlettC, HolensteinF and SterneJ. (2003). How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess, 7:1–76.
32.
BeggCB and MazumdarM. (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50:1088–1101.
33.
LiT, GuJ, YangO, WangJ, WangY and KongJ. (2020). Bone marrow mesenchymal stem cell-derived exosomal miRNA-29c decreases cardiac ischemia/reperfusion injury through inhibition of excessive autophagy via the PTEN/Akt/mTOR signaling pathway. Circ J, 84:1304–1311.
34.
ParkH, ParkH, MunD, KangJ, KimH, KimM, CuiS, LeeS-H and JoungB. (2018). Extracellular vesicles derived from hypoxic human mesenchymal stem cells attenuate GSK3 beta expression via miRNA-26a in an ischemia-reperfusion injury model. Yonsei Med J, 59:736–745.
35.
WuQ, WangJ, TanWLW, JiangY, WangS, LiQ, YuX, TanJ, LiuS, et al. (2020). Extracellular vesicles from human embryonic stem cell-derived cardiovascular progenitor cells promote cardiac infarct healing through reducing cardiomyocyte death and promoting angiogenesis. Cell Death Dis, 11:354.
36.
ZhangCS, ShaoK, LiuCW, LiCJ and YuBT. (2019). Hypoxic preconditioning BMSCs-exosomes inhibit cardiomyocyte apoptosis after acute myocardial infarction by upregulating microRNA-24. Eur Rev Med Pharmacol Sci, 23:6691–6699.
37.
ZhuJ, LuK, ZhangN, ZhaoY, MaQ, ShenJ, LinY, XiangP, TangY, et al. (2018). Myocardial reparative functions of exosomes from mesenchymal stem cells are enhanced by hypoxia treatment of the cells via transferring microRNA-210 in an nSMase2-dependent way. Artif Cells Nanomed Biotechnol, 46:1659–1670.
38.
SunL, ZhuW, ZhaoP, WangQ, FanB, ZhuY, LuY, ChenQ, ZhangJ and ZhangF. (2020). Long noncoding RNA UCA1 from hypoxia-conditioned hMSC-derived exosomes: a novel molecular target for cardioprotection through miR-873-5p/XIAP axis. Cell Death and Disease, 11:696.
39.
LaluMM, MazzarelloS, ZlepnigJ, DongYYR, MontroyJ, McIntyreL, DevereauxPJ, StewartDJ, David MazerC, et al. (2018). Safety and efficacy of adult stem cell therapy for acute myocardial infarction and ischemic heart failure (SafeCell Heart): a systematic review and meta-analysis. Stem Cells Transl Med, 7:857–866.
40.
GyöngyösiM, WojakowskiW, NavareseEP and MoyeL. (2016). Meta-analyses of human cell-based cardiac regeneration therapies: controversies in meta-analyses results on cardiac cell-based regenerative studies. Circ Res, 118:1254–1263.
41.
SahooS and LosordoDW. (2014). Exosomes and cardiac repair after myocardial infarction. Circ Res, 114:333–344.
42.
FuS, ZhangY, LiY, LuoL, ZhaoY and YaoY. (2020). Extracellular vesicles in cardiovascular diseases. Cell Death Discov, 6:68.
43.
SuzukiE, FujitaD, TakahashiM, ObaS and NishimatsuH. (2016). Stem cell-derived exosomes as a therapeutic tool for cardiovascular disease. World J Stem Cells, 8:297–305.
44.
McKeown SR. (2014). Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol, 87:20130676.
45.
RehmanJ, TraktuevD, LiJ, Merfeld-ClaussS, Temm-GroveCJ, BovenkerkJE, PellCL, JohnstoneBH, ConsidineRV and MarchKL. (2004). Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation, 109:1292–1298.
46.
ThangarajahH, VialIN, ChangE, El-FtesiS, JanuszykM, ChangEI, PaternoJ, NeofytouE, LongakerMT and GurtnerGC. (2009). IFATS collection: adipose stromal cells adopt a proangiogenic phenotype under the influence of hypoxia. Stem Cells, 27:266–274.
47.
HuX, XuY, ZhongZ, WuY, ZhaoJ, WangY, ChengH, KongM, ZhangF, et al. (2016). A large-scale investigation of hypoxia-preconditioned allogeneic mesenchymal stem cells for myocardial repair in nonhuman primates: paracrine activity without remuscularization. Circ Res, 118:970–983.
48.
KucharzewskaP, ChristiansonHC, WelchJE, SvenssonKJ, FredlundE, RingnérM, MörgelinM, Bourseau-GuilmainE, BengzonJ and BeltingM. (2013). Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A, 110:7312–7317.
49.
Burnley-HallN, WillisG, DavisJ, ReesDA and JamesPE. (2017). Nitrite-derived nitric oxide reduces hypoxia-inducible factor 1 alpha-mediated extracellular vesicle production by endothelial cells. Nitric Oxide Biol Chem, 63:1–12.
50.
Fafián-LaboraJA, Rodríguez-NavarroJA and O'LoghlenA. (2020). Small extracellular vesicles have GST activity and ameliorate senescence-related tissue damage. Cell Metab, 32:71–86.e5.
51.
GandhamS, SuX, WoodJ, NoceraAL, AlliSC, MilaneL, ZimmermanA, AmijiM and IvanovAR. (2020). Technologies and standardization in research on extracellular vesicles. Trends Biotechnol, 38:1066–1098.
52.
SaludasL, OliveiraCC, RoncalC, Ruiz-VillalbaA, PrósperF, GarbayoE and Blanco-PrietoMJ. (2021). Extracellular vesicle-based therapeutics for heart repair. Nanomaterials (Basel), 11:570.
53.
LamichhaneTN, RaikerRS and JaySM. (2015). Exogenous DNA loading into extracellular vesicles via electroporation is size-dependent and enables limited gene delivery. Mol Pharm, 12:3650–3657.
54.
FuhrmannG, SerioA, MazoM, NairR and StevensMM. (2015). Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J Control Release, 205:35–44.
55.
ParryHA, MobleyCB, MumfordPW, RomeroMA, HaunCT, ZhangY, RobersonPA, ZempleniJ, FerrandoAA, et al. (2019). Bovine milk extracellular vesicles (EVs) modification elicits skeletal muscle growth in rats. Front Physiol, 10:436.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
